Cargando…
ADAM12 is an independent predictor of poor prognosis in liver cancer
Disintegrin and metalloproteinase 12 (ADAM12) is thought to trigger the occurrence and development of numerous tumours, including colorectal, breast, and pancreatic cancers. On the basis of The Cancer Genome Atlas (TCGA) datasets, in this study, the relationship between ADAM12 gene expression and he...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033838/ https://www.ncbi.nlm.nih.gov/pubmed/35459884 http://dx.doi.org/10.1038/s41598-022-10608-y |
_version_ | 1784692987143389184 |
---|---|
author | Du, Shuangqiu Sun, Linlin Wang, Yun Zhu, Wenhao Gao, Jialin Pei, Wenjun Zhang, Yao |
author_facet | Du, Shuangqiu Sun, Linlin Wang, Yun Zhu, Wenhao Gao, Jialin Pei, Wenjun Zhang, Yao |
author_sort | Du, Shuangqiu |
collection | PubMed |
description | Disintegrin and metalloproteinase 12 (ADAM12) is thought to trigger the occurrence and development of numerous tumours, including colorectal, breast, and pancreatic cancers. On the basis of The Cancer Genome Atlas (TCGA) datasets, in this study, the relationship between ADAM12 gene expression and hepatocellular carcinoma (HCC), the prognostic value of this relationship, and the potential mechanisms influencing HCC development were evaluated. The results showed that the ADAM12 gene was significantly and highly expressed in liver cancer tissue. The high expression of the ADAM12 gene in liver cancer tissue significantly and positively correlated with T stage, pathological stage, and residual tumour. Kaplan–Meier and Cox regression analyses revealed that ADAM12 gene expression is an independent risk factor influencing the prognosis of patients with liver cancer. Pathway analyses of ADAM12 in HCC revealed ADAM12-correlated signalling pathways, and the expression level of ADAM12 was associated with immune cell infiltration. In vitro experiments demonstrated that the expression level of ADAM12 in Huh-7 and Hep3B cells was significantly higher than that in other HCC cells. ShRNA transfection experiments confirmed that the expression levels of TGF-β and Notch pathway-related proteins were significantly decreased. An EdU cell proliferation assay showed that a low level of ADAM12 gene expression significantly inhibited the proliferative activity of HCC cells. Cell cycle experiments showed that low ADAM12 expression blocked the G1/S phase transition. Overall, this research revealed that high ADAM12 gene expression implies a poor prognosis for patients with primary liver cancer. In addition, it is a potential indicator for the diagnosis of liver cancer. |
format | Online Article Text |
id | pubmed-9033838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90338382022-04-25 ADAM12 is an independent predictor of poor prognosis in liver cancer Du, Shuangqiu Sun, Linlin Wang, Yun Zhu, Wenhao Gao, Jialin Pei, Wenjun Zhang, Yao Sci Rep Article Disintegrin and metalloproteinase 12 (ADAM12) is thought to trigger the occurrence and development of numerous tumours, including colorectal, breast, and pancreatic cancers. On the basis of The Cancer Genome Atlas (TCGA) datasets, in this study, the relationship between ADAM12 gene expression and hepatocellular carcinoma (HCC), the prognostic value of this relationship, and the potential mechanisms influencing HCC development were evaluated. The results showed that the ADAM12 gene was significantly and highly expressed in liver cancer tissue. The high expression of the ADAM12 gene in liver cancer tissue significantly and positively correlated with T stage, pathological stage, and residual tumour. Kaplan–Meier and Cox regression analyses revealed that ADAM12 gene expression is an independent risk factor influencing the prognosis of patients with liver cancer. Pathway analyses of ADAM12 in HCC revealed ADAM12-correlated signalling pathways, and the expression level of ADAM12 was associated with immune cell infiltration. In vitro experiments demonstrated that the expression level of ADAM12 in Huh-7 and Hep3B cells was significantly higher than that in other HCC cells. ShRNA transfection experiments confirmed that the expression levels of TGF-β and Notch pathway-related proteins were significantly decreased. An EdU cell proliferation assay showed that a low level of ADAM12 gene expression significantly inhibited the proliferative activity of HCC cells. Cell cycle experiments showed that low ADAM12 expression blocked the G1/S phase transition. Overall, this research revealed that high ADAM12 gene expression implies a poor prognosis for patients with primary liver cancer. In addition, it is a potential indicator for the diagnosis of liver cancer. Nature Publishing Group UK 2022-04-22 /pmc/articles/PMC9033838/ /pubmed/35459884 http://dx.doi.org/10.1038/s41598-022-10608-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Du, Shuangqiu Sun, Linlin Wang, Yun Zhu, Wenhao Gao, Jialin Pei, Wenjun Zhang, Yao ADAM12 is an independent predictor of poor prognosis in liver cancer |
title | ADAM12 is an independent predictor of poor prognosis in liver cancer |
title_full | ADAM12 is an independent predictor of poor prognosis in liver cancer |
title_fullStr | ADAM12 is an independent predictor of poor prognosis in liver cancer |
title_full_unstemmed | ADAM12 is an independent predictor of poor prognosis in liver cancer |
title_short | ADAM12 is an independent predictor of poor prognosis in liver cancer |
title_sort | adam12 is an independent predictor of poor prognosis in liver cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033838/ https://www.ncbi.nlm.nih.gov/pubmed/35459884 http://dx.doi.org/10.1038/s41598-022-10608-y |
work_keys_str_mv | AT dushuangqiu adam12isanindependentpredictorofpoorprognosisinlivercancer AT sunlinlin adam12isanindependentpredictorofpoorprognosisinlivercancer AT wangyun adam12isanindependentpredictorofpoorprognosisinlivercancer AT zhuwenhao adam12isanindependentpredictorofpoorprognosisinlivercancer AT gaojialin adam12isanindependentpredictorofpoorprognosisinlivercancer AT peiwenjun adam12isanindependentpredictorofpoorprognosisinlivercancer AT zhangyao adam12isanindependentpredictorofpoorprognosisinlivercancer |